Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Remitly Global Inc (RELY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Remitly Global Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.79 (market cap $4.49B), while Remitly Global Inc trades at $23.27 (market cap $5.08B). The key difference: ACADIA Pharmaceuticals Inc. and Remitly Global Inc are close in size by market cap, and Remitly Global Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | RELY | |
|---|---|---|
Market Cap | $4.49B | $5.08B |
Sector | Health | Technology |
52-Week High | $28.06 | $24.28 |
52-Week Low | $20.06 | $12.20 |
Enterprise Value | $3.69B | $4.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
RELY trades at $24.13, up 1.6% on the day, with strong bullish technical signals from moving averages and a consensus analyst price target of $25.67. The company shows accelerating revenue growth, reaching $1.64 billion in 2025, and has achieved profitability with net income of $67.93 million. Recent news highlights expansion into Canada and new business features driving investor optimism.
Outlook remains positive due to sustained revenue growth and market expansion, though high valuation multiples and overbought RSI levels pose near-term risks. The stock offers growth potential in digital payments but faces execution and competitive pressures in the remittance space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
